Hyloris enrols first patient in four-arm clinical trial

June 22, 2023
Research and Development Genito-Urinary system, Hyloris, bladder pain, clinical trial, cystitis

Belgian specialty biopharmaceutical company Hyloris has announced that it has enrolled the first patient in its four-arm interstitial cystitis/bladder pain …

money_pills_2

Zymeworks to open new EU HQ in Dublin, Ireland

June 22, 2023
Business Services Dublin, Oncology, Zymeworks, headquarters, regulatory affiars

Canadian biotech company Zymeworks has announced plans to open its new Clinical and Regulatory EU headquarters in Dublin, Ireland. Zymework …

Eli Lilly to acquire DICE Therapeutics for immunology innovations

June 21, 2023
Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology

Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …

mufid-majnun-cm1au42fnrg-unsplash_3

GSK shares positive data for RSV vaccine

June 21, 2023
Research and Development GSK, Immunology, RSV, Vaccine, clinical trial

GSK have announced new positive data from the AReSVi-006 phase 3 trial which assessed the efficacy of a single dose …

national-cancer-institute-kmvohcb-w5g-unsplash_1

FDA approves Pfizerโ€™s HRR mCRPC drug

June 21, 2023
Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer

US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …

PharmaTher and Vitruvias sign collaboration agreement to commercialise ketamine-based treatment in the US

June 21, 2023
Medical Communications Ketamine, Neurology, PharmaTher, Vitruvias, commercialisation

Specialty pharmaceutical companies, Canadian PharmaTher and US-based Vitruvias, have entered into a commercialisation partnership to bring Ketarx products to the …

Sirnaomics advances isSCC candidate into late-stage clinical development

June 20, 2023
Research and Development FDA, Oncology, Sirnaomics, clinical trial, isSCC

Global RNA therapeutics biopharmaceutical company Sirnaomics has announced that it has advanced its Squamous Cell Carcinoma in situ (isSCC) candidate …

Abu Dhabiโ€™s Department of Health, M42 and AbbVie enter strategic partnership

June 20, 2023
Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership

Abu Dhabiโ€™s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …

GSK announces extension of FDAโ€™s review for momelotinib

June 20, 2023
Medical Communications FDA, GSK, Oncology, momelotinib, new drug application

GSK has announced that the US Food and Drug Administration (FDA) has extended its review period for the new drug …

Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal

June 20, 2023
Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera

Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …

Immodulon appoints Josefine Roemmler-Zehrer as chief medical officer

June 20, 2023
Immodulon, Josefine Roemmler-Zehrer, appointment, chief medical officer

Cancer immunotherapy company Immodulon has announced that it has appointed Josefine Roemmler-Zehrer as chief medical officer, bringing with her vast …

Scientists develop 3D printed pills for time-controlled release

June 19, 2023
Research and Development 3d printed pills, 3d printing, Max Planck Insititute, Pharmacy, University of California

A team of scientists at the Max Planck Institute (MPI) for Informatics, Germany, and the University of California, US, have …

Vaxxas opens manufacturing facility for needle-free vaccine patch

June 19, 2023
Research and Development Immunology, Vaxxas, manufacturing, needle-free vaccines, vaccines

Clinical stage biotech company Vaxxas has announced that it is opening a biomedical manufacturing facility in Brisbane, Australia, for the …

ImmuPharma initiates phase 2/3 clinical trial for lupus treatment

June 19, 2023
Research and Development Avion Pharmaceuticals, ImmuPharma, Immunology, Lupus, clinical trial

ImmuPharma has announced that it will commence a phase 2/3 adaptive clinical trial of P140 (Lupuzor) in patients with systemic …

Rani Therapeuticsโ€™ oral โ€˜robotic pillโ€™ delivers injection trans-enterically

June 19, 2023
Medical Communications Osteoporosis, Rani Therapeutics, injection, osteoporosis, robotic pill, robotics

US Rani Therapeutics, a clinical-stage biotherapeutics company, has reported new results from its phase 1 trial into the RaniPill capsule …

LEO Pharma appoints Leanne Walsh as general manager and vice president for UK and Ireland

June 19, 2023
LEO Pharma, appointment, general manager, vice president

Medical dermatology company LEO Pharma has announced that it has appointed Leanne Walsh as its new general manager and vice …

document-428331_960_720

Nordic Bioscience receives FDA Letter of Support for biomarker in aggressive tumour fibrosis

June 16, 2023
Research and Development FDA, Nordic Bioscience, Oncology, Roche, tumour fibrosis

Danish biomarker company Nordic Bioscience has announced that the US Food and Drug Administration (FDA) has awarded it a Letter …

Takeda and HUTCHMEDโ€™s cancer drug shown to prolong overall survival

June 16, 2023
Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …

Antibiotics image

FDA gives Eagle Pharmaceuticals Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for SCABP drug

June 15, 2023
Research and Development Eagle Pharmaceuticals, FDA, FDA fast-track, Immunology, SCABP

US-based pharmaceutical company Eagle Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted its severe community-acquired …

shaking-hands-gb7ac17374_1920

Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders

June 15, 2023
Research and Development Astellas, Cullgen, Oncology, protein degraders

Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have entered into a strategic research …

The Gateway to Local Adoption Series

Latest content